Simvastatin–ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study
作者: Shang-Hung ChangLung-Sheng WuCheng-Hung LeeChi-Tai KuoJia-Rou LiuMing-Shien WenWei-Jan ChenLai-Chu SeeYung-Hsin Yeh
作者单位: 1Chang Gung University and Department of Cardiology, Chang Gung Memorial Hospital, Taipei, Taiwan
2Department of Public Health, College of Medicine, Chang Gung University, Taiwan
3Biostatistics Core Laboratory, Molecular Medicine Research Center, Chang Gung University, Taiwan
刊名: International Journal of Cardiology, 2015, Vol.190 , pp.20-25
来源数据库: Elsevier Journal
DOI: 10.1016/j.ijcard.2015.04.121
关键词: Simvastatin–ezetimibeType 2 diabetesMajor adverse cardiac eventsStatins
原始语种摘要: Abstract(#br)Background(#br)Recent trials have shown a reduction in the risk of major adverse cardiac events (MACE) with simvastatin–ezetimibe therapy in patients with acute coronary syndrome. The potential benefits of simvastatin–ezetimibe for patients at a lower risk of MACE are unclear. This study aimed to investigate the differences of MACE risk between patients with type 2 diabetes mellitus (DM) using simvastatin–ezetimibe or high potency statins.(#br)Methods(#br)This population-based dynamic cohort study used data from the Taiwan National Health Insurance Database. The study subjects were patients with type 2 DM, aged between 40 and 75years. The simvastatin–ezetimibe group took simvastatin–ezetimibe only, and the statin group took atorvastatin or rosuvastatin but...
全文获取路径: Elsevier  (合作)
影响因子:5.509 (2012)

  • 糖尿病 伙伴
  • events 定时
  • potency 潜力
  • adverse 逆的
  • lower 降下
  • cardiac 贲门
  • cohort 伙伴
  • diabetes 伙伴
  • associated 相关的
  • combination 聚形
  • therapy 治疗